Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
Bayer and Mammoth Biosciences to collaborate on novel gene editing technolog
January 10, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022